Treats Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism. ANDA 77828, held by Sun Pharm Inds. Carbidopa; Levodopa.
As of Nov 16, 2026, ANDA 77828 (Carbidopa And Levodopa), held by Sun Pharm Inds, was first approved by FDA on Aug 23, 2007, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Carbidopa and levodopa extended-release tablets are indicated in the treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 23, 2007 | Original application | Approved | None posted |
| Carbidopa And Levodopa25MG;100MG · tablet, extended release;oral | Carbidopa; Levodopa | Discontinued |
| Carbidopa And Levodopa50MG;200MG · tablet, extended release;oral | Carbidopa; Levodopa | Discontinued |
| Sep 24, 2015 | Supplement 8Labeling · Standard review | Approved | None posted |
| Apr 3, 2013 | Supplement 4Labeling · Standard review | Approved | None posted |
| Aug 23, 2007 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters